KELOWNA, B.C., Nov. 17, 2020 /CNW/ - The Valens Company
Inc. (TSX: VLNS) (OTCQX: VLNCF) (the "Company" or "The Valens
Company"), a global leader in the end-to-end
development and manufacturing of innovative, cannabinoid-based
products, today announced the addition of SōRSE Clear, a stable,
clear emulsion with a minimal sensory profile, to the SōRSE by
Valens offering for CBD isolate product formats.
SōRSE Technology is a water-soluble emulsion technology
designed for product developers to provide consumers with a more
consistent cannabinoid experience with user-controlled dosing,
demonstrated shelf-stability, and safe ingredients. The Valens
Company has been leveraging this emulsion technology to transform
cannabis extracts into water-soluble forms and to infuse beverages,
edibles and topicals without a cannabis aroma and after-taste.
"As the exclusive partner for the development and custom
manufacturing of best-in-class cannabis derivative products in
Canada, having access to the
highest quality cannabinoid emulsion technology is critically
important," said Tyler Robson, Chief
Executive Officer of The Valens Company. "We have made great
strides revolutionizing many of our product lines with SōRSE by
Valens, including more mature formats such as tinctures, and the
addition of SōRSE Clear will only deepen our ability to innovate a
diverse portfolio of products for the forthcoming 3.0 market."
SōRSE Clear is currently available in a liquid format and
contains safe, vegan, allergen-free ingredients. The new emulsion
offering features multiple benefits including stability, safety,
improved sensory experience, homogeneity, and seamless integration.
SōRSE Clear also complies with all the main safety and testing
protocols, including Good Manufacturing Practices (GMP) and The
Global Safety Food Initiative (GFSI).
Howard Lee, Chief Executive
Officer of SōRSE, said, "We believe that SōRSE Clear is a
game-changer for the cannabis industry and we have no doubt that
The Valens Company will harness this technology to continue to
formulate the most innovative, premium cannabis-infused products
for Canadian consumers."
About The Valens Company
The Valens Company is a global leader in the end-to-end
development and manufacturing of innovative, cannabinoid-based
products. The Company is focused on being the partner of choice for
leading Canadian and international cannabis brands by providing
best-in-class, proprietary services including CO2, ethanol,
hydrocarbon, solvent-less and terpene extraction, analytical
testing, formulation and product development and custom
manufacturing. The Valens Company is the largest manufacturer of
derivative products in Canada with
an annual capacity of 425,000 kg of dried cannabis and hemp biomass
at our purpose-built facility in Kelowna,
British Columbia which is in the process of becoming
European Union (EU) Good Manufacturing Practices (GMP) compliant.
The Valens Company currently offers a wide range of product
formats, including tinctures, two-piece caps, soft gels, oral
sprays and vape pens as well as beverages, concentrates, topicals,
edibles, injectables, natural health products and has a strong
pipeline of next-generation products in development for future
release. Finally, The Valens Company's wholly-owned subsidiary
Valens Labs is a Health Canada
licensed ISO 17025 accredited cannabis testing lab providing
sector-leading analytical services and has partnered with Thermo
Fisher Scientific to develop a Centre of Excellence in Plant-Based
Science. For more information, please visit
http://thevalenscompany.com. The Valens Company's investor deck can
be found specifically at
http://thevalenscompany.com/investors/.
About SōRSE Technology
SōRSE Technology Corporation is a water-soluble emulsion
technology designed for product developers to provide consumers
with a better, more consistent cannabinoid experience with greater
bioavailability, near-perfect dosing, shelf-stability, and safe
ingredients. Its patent-pending technology converts oil into SōRSE,
a proprietary water-soluble emulsion, for infusing CBD and other
functional ingredients into beverages, food items, topicals, and
medical applications. SōRSE Technology currently powers more than
45 leading products in the CBD space.
Notice regarding Forward Looking Statements
All information included in this press release, including any
information as to the future financial or operating performance and
other statements of The Valens Company that express management's
expectations or estimates of future performance, other than
statements of historical fact, constitute forward-looking
information or forward-looking statements within the meaning of
applicable securities laws and are based on expectations, estimates
and projections as of the date hereof. Forward-looking statements
are included for the purpose of providing information about
management's current expectations and plans relating to the future.
Wherever possible, words such as "plans", "expects", "scheduled",
"trends", "indications", "potential", "estimates", "predicts",
"anticipate", "to establish", "believe", "intend", "ability to", or
statements that certain actions, events or results "may", "could",
"would", "might", "will", or are "likely" to be taken, occur or be
achieved, or the negative of these words or other variations
thereof, have been used to identify such forward-looking
information. Specific forward-looking statements include, without
limitation, all disclosure regarding future results of operations,
economic conditions and anticipated courses of action. Investors
and other parties are advised that there is not necessarily any
correlation between the number of SKUs manufactured and shipped and
revenue and profit, and undue reliance should not be placed on such
information.
The risks and uncertainties that may affect forward-looking
statements include, among others, regulatory risk,
United States border crossing and
travel bans, reliance on licenses, expansion of facilities,
competition, dependence on supply of cannabis and reliance on other
key inputs, dependence on senior management and key personnel,
general business risk and liability, regulation of the cannabis
industry, change in laws, regulations and guidelines, compliance
with laws, reliance on a single facility, limited operating
history, vulnerability to rising energy costs, unfavourable
publicity or consumer perception, product liability, risks related
to intellectual property, product recalls, difficulties with
forecasts, management of growth and litigation, many of which are
beyond the control of The Valens Company. For a more comprehensive
discussion of the risks faced by The Valens Company, and which may
cause the actual financial results, performance or achievements of
The Valens Company to be materially different from estimated future
results, performance or achievements expressed or implied by
forward-looking information or forward-looking statements, please
refer to The Valens Company's latest Annual Information Form filed
with Canadian securities regulatory authorities at www.sedar.com or
on The Valens Company's website at www.thevalenscompany.com. The
risks described in such Annual Information Form are hereby
incorporated by reference herein. Although the forward-looking
statements contained herein reflect management's current beliefs
and reasonable assumptions based upon information available to
management as of the date hereof, The Valens Company cannot be
certain that actual results will be consistent with such
forward-looking information. The Valens Company cautions you not to
place undue reliance upon any such forward-looking statements. The
Valens Company disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
applicable law. Nothing herein should be construed as either an
offer to sell or a solicitation to buy or sell securities of The
Valens Company.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/the-valens-company-adds-clear-emulsion-to-srse-by-valens-offering-301174390.html
SOURCE The Valens Company Inc.
